StockNews.AISignal intelligence
Phio Pharmaceuticals Corp. · NASDAQ · Healthcare
Browse public PHIO signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Phio Pharmaceuticals Corp. reported promising results from its Phase 1b clinical trial for PH-762, leading to a rise in share price. The positive trial outcomes are critical as they enhance investor confidence in the drug's therapeutic efficacy, potentially leading to significant future investment and market interest.
View signal analysisPHIO stock soared 378.7% with high trading volume of 201.04 million. Complete response achieved in 2 patients with 100% tumor clearance. Phase 1b study shows no significant adverse events for PH-762. Preclinical studies support PH-762's tumor growth inhibition and safety. PH-762 enhances T cell response in tumor microenvironment.
View signal analysis- Phio Pharmaceuticals Corp. approved a reverse stock split at a ratio of 1-for-9. - The reverse stock split aims to increase the per share trading price. - Number of outstanding common stock shares will decrease significantly post-split. - Company's transfer agent will handle the exchange process for stockholders. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Corporate Developments
View signal analysis